<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498524</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001258</org_study_id>
    <nct_id>NCT00498524</nct_id>
  </id_info>
  <brief_title>Risk of Life-threatening Heart Rhythm Disturbances in Siblings</brief_title>
  <acronym>SIBFIB</acronym>
  <official_title>The Sibling Concordance for Implantable Cardioverter-defibrillator Therapies in Ischemic Cardiomyopathy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if heredity influences the risk of life-threatening
      heart rhythms (ventricular tachycardia and ventricular fibrillation) after heart attack
      (myocardial infarction).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Greater than 400,000 persons die suddenly each year in the US. The implantable
      cardioverter-defibrillator (ICD) has revolutionized the primary prevention of sudden cardiac
      death (SCD) following myocardial infarction (MI), however, risk stratification remains
      limited and rests solely on the identification of left ventricular dysfunction. The goal of
      this study is to determine if genetic factors influence the risk of ventricular arrhythmia
      remotely after myocardial infarction.

      In order to determine if ventricular tachycardia or ventricular fibrillation remotely after
      MI is a heritable trait, we will conduct a family based case-control sibling study of
      patients who have received an ICD for ischemic cardiomyopathy. As a first step, we will
      utilize the GENECARD registry, an existing family linkage study of premature cardiovascular
      disease, to determine the prevalence of sibling concordance for ICD implantation following
      MI. Probands and siblings in the GENECARD study will be surveyed regarding their ICD history.
      The sibling recurrence risk ratio for ICD implantation following MI and subsequent ICD
      therapies will be used to estimate the sample size required to validate heritability, in a
      larger patient population. In the validation phase of this protocol, we will use a (1) single
      healthcare system database (Duke Cardiovascular Databank) and a (2) regional population-based
      registry, in order to determine concordance for ICD therapies. Patients who agree to
      participate and provide informed consent will be surveyed regarding their personal ICD
      history and that of their siblings. The prevalence of ICD therapies will be ascertained in
      the probands, siblings, and the overall cohort. Sibling concordance for ICD implantation and
      sibling concordance for subsequent appropriate ICD therapies will be used to determine the
      sibling recurrence risk ratio for appropriate ICD therapies remotely after MI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ICD Discharge</measure>
    <time_frame>Long-term follow up</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2047</enrollment>
  <condition>Defibrillators, Implantable</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Tachycardias, Ventricular</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Sib who has received an ICD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Sib who has not received an ICD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>Received an ICD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>Have not received an ICD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post-MI population with LV dysfunction and an implantable cardioverter-defibrillator.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients must be alive

          -  have a history of coronary artery disease / myocardial infarction

          -  left ventricular ejection fraction â‰¤ 35%

          -  received an implantable cardioverter- defibrillator

        Exclusion Criteria:

          -  nonischemic cardiomyopathy

          -  Pre-identified hereditary arrhythmia syndrome (e.g. long QT syndrome, Brugada
             syndrome, etc)

          -  left ventricular ejection fraction &gt;35%

          -  no implantable cardioverter-defibrillator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick M Hranitzky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan P Piccini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center, Division of Cardiology - Electrophysiology Section</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jonathan P Piccini</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <keyword>ischemic cardiomyopathy</keyword>
  <keyword>ventricular arrhythmias</keyword>
  <keyword>sibling concordance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

